| Company/Division name | Enzene Biosciences, Ltd |
| Parent company | Alkem Laboratories, Ltd |
| Type of work | Manufacturing |
| Reshoring category: | Foreign Direct Investment |
| Total number of jobs (added or to be added): | 300 |
| Year reshoring announced: | 2023 |
| Year reshoring implemented or to be implemented: | 2024 |
| Country(ies) from which reshored: | India |
| City reshored to: | Hopewell |
| State(s) reshored to: | NJ |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | Cell line engineering drug product |
| What domestic positive factors made reshoring more attractive? | Government Incentives, Infrastructure, Skilled workforce availability/training |
